Hjem › Akut myelogen leukemi › Vermont
Kliniske studier for Akut myelogen leukemi i Vermont
7 studier for Akut myelogen leukemi søker deltakere på steder i Vermont.
Byer i Vermont
Offisiell studietekst (engelsk)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Vermont Medical Center, Burlington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Vermont, Burlington
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.